Pfizer PFE will report its second-quarter 2025 earnings on Aug. 5, before market open. The Zacks Consensus Estimate for sales ...

Pfizer has lagged behind the broader market over the past year, but analysts maintain a cautiously optimistic outlook on the ...

In the latest trading session, Pfizer (PFE) closed at $23.27, marking a -2.29% move from the previous day. The stock's change was less than the S&P 500's daily loss of 0.37%. At the same time, the Dow ...

Pfizer's (NYSE:PFE) stock up by 7.7% over the past three months. However, we decided to study the company's mixed-bag of ...

Pfizer (NYSE: PFE) was on top of the world when it came to earnings and stock price performance. This was in early pandemic times, as the company's coronavirus treatment and vaccine generated enormous ...

In 2022, it became the first company in the biopharmaceutical industry to generate $100 billion in annual sales. Let's look deeper, and discuss whether the recent development makes Pfizer stock a buy.

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Pfizer's chronic myeloid leukemia drug, Bosulif, was rejected by U.K. regulators. Pharmaceutical companies have been facing major revenue losses from patent expirations. CVS Caremark threats ...

Pfizer's decision to license SSGJ-707 doesn't make its stock a buy in and of itself. However, the drug candidate is another valuable asset that will be part of the company's plan to improve its ...